Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults

Abstract The vaccine efficacy of standard-dose seasonal inactivated influenza vaccines (S-IIV) can be improved by the use of vaccines with higher antigen content or adjuvants. We conducted a randomized controlled trial in older adults to compare cellular and antibody responses of S-IIV versus enhanc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Athena P. Y. Li, Carolyn A. Cohen, Nancy H. L. Leung, Vicky J. Fang, Shivaprakash Gangappa, Suryaprakash Sambhara, Min Z. Levine, A. Danielle Iuliano, Ranawaka A. P. M. Perera, Dennis K. M. Ip, J. S. Malik Peiris, Mark G. Thompson, Benjamin J. Cowling, Sophie A. Valkenburg
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ff75dec103104784802c673035cff753
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ff75dec103104784802c673035cff753
record_format	dspace
spelling	oai:doaj.org-article:ff75dec103104784802c673035cff7532021-12-02T14:03:56ZImmunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults10.1038/s41541-021-00289-52059-0105https://doaj.org/article/ff75dec103104784802c673035cff7532021-02-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00289-5https://doaj.org/toc/2059-0105Abstract The vaccine efficacy of standard-dose seasonal inactivated influenza vaccines (S-IIV) can be improved by the use of vaccines with higher antigen content or adjuvants. We conducted a randomized controlled trial in older adults to compare cellular and antibody responses of S-IIV versus enhanced vaccines (eIIV): MF59-adjuvanted (A-eIIV), high-dose (H-eIIV), and recombinant-hemagglutinin (HA) (R-eIIV). All vaccines induced comparable H3-HA-specific IgG and elevated antibody-dependent cellular cytotoxicity (ADCC) activity at day 30 post vaccination. H3-HA-specific ADCC responses were greatest following H-eIIV. Only A-eIIV increased H3-HA-IgG avidity, HA-stalk IgG and ADCC activity. eIIVs also increased polyfunctional CD4+ and CD8+ T cell responses, while cellular immune responses were skewed toward single-cytokine-producing T cells among S-IIV subjects. Our study provides further immunological evidence for the preferential use of eIIVs in older adults as each vaccine platform had an advantage over the standard-dose vaccine in terms of NK cell activation, HA-stalk antibodies, and T cell responses.Athena P. Y. LiCarolyn A. CohenNancy H. L. LeungVicky J. FangShivaprakash GangappaSuryaprakash SambharaMin Z. LevineA. Danielle IulianoRanawaka A. P. M. PereraDennis K. M. IpJ. S. Malik PeirisMark G. ThompsonBenjamin J. CowlingSophie A. ValkenburgNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Athena P. Y. Li Carolyn A. Cohen Nancy H. L. Leung Vicky J. Fang Shivaprakash Gangappa Suryaprakash Sambhara Min Z. Levine A. Danielle Iuliano Ranawaka A. P. M. Perera Dennis K. M. Ip J. S. Malik Peiris Mark G. Thompson Benjamin J. Cowling Sophie A. Valkenburg Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults
description	Abstract The vaccine efficacy of standard-dose seasonal inactivated influenza vaccines (S-IIV) can be improved by the use of vaccines with higher antigen content or adjuvants. We conducted a randomized controlled trial in older adults to compare cellular and antibody responses of S-IIV versus enhanced vaccines (eIIV): MF59-adjuvanted (A-eIIV), high-dose (H-eIIV), and recombinant-hemagglutinin (HA) (R-eIIV). All vaccines induced comparable H3-HA-specific IgG and elevated antibody-dependent cellular cytotoxicity (ADCC) activity at day 30 post vaccination. H3-HA-specific ADCC responses were greatest following H-eIIV. Only A-eIIV increased H3-HA-IgG avidity, HA-stalk IgG and ADCC activity. eIIVs also increased polyfunctional CD4+ and CD8+ T cell responses, while cellular immune responses were skewed toward single-cytokine-producing T cells among S-IIV subjects. Our study provides further immunological evidence for the preferential use of eIIVs in older adults as each vaccine platform had an advantage over the standard-dose vaccine in terms of NK cell activation, HA-stalk antibodies, and T cell responses.
format	article
author	Athena P. Y. Li Carolyn A. Cohen Nancy H. L. Leung Vicky J. Fang Shivaprakash Gangappa Suryaprakash Sambhara Min Z. Levine A. Danielle Iuliano Ranawaka A. P. M. Perera Dennis K. M. Ip J. S. Malik Peiris Mark G. Thompson Benjamin J. Cowling Sophie A. Valkenburg
author_facet	Athena P. Y. Li Carolyn A. Cohen Nancy H. L. Leung Vicky J. Fang Shivaprakash Gangappa Suryaprakash Sambhara Min Z. Levine A. Danielle Iuliano Ranawaka A. P. M. Perera Dennis K. M. Ip J. S. Malik Peiris Mark G. Thompson Benjamin J. Cowling Sophie A. Valkenburg
author_sort	Athena P. Y. Li
title	Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults
title_short	Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults
title_full	Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults
title_fullStr	Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults
title_full_unstemmed	Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults
title_sort	immunogenicity of standard, high-dose, mf59-adjuvanted, and recombinant-ha seasonal influenza vaccination in older adults
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/ff75dec103104784802c673035cff753
work_keys_str_mv	AT athenapyli immunogenicityofstandardhighdosemf59adjuvantedandrecombinanthaseasonalinfluenzavaccinationinolderadults AT carolynacohen immunogenicityofstandardhighdosemf59adjuvantedandrecombinanthaseasonalinfluenzavaccinationinolderadults AT nancyhlleung immunogenicityofstandardhighdosemf59adjuvantedandrecombinanthaseasonalinfluenzavaccinationinolderadults AT vickyjfang immunogenicityofstandardhighdosemf59adjuvantedandrecombinanthaseasonalinfluenzavaccinationinolderadults AT shivaprakashgangappa immunogenicityofstandardhighdosemf59adjuvantedandrecombinanthaseasonalinfluenzavaccinationinolderadults AT suryaprakashsambhara immunogenicityofstandardhighdosemf59adjuvantedandrecombinanthaseasonalinfluenzavaccinationinolderadults AT minzlevine immunogenicityofstandardhighdosemf59adjuvantedandrecombinanthaseasonalinfluenzavaccinationinolderadults AT adanielleiuliano immunogenicityofstandardhighdosemf59adjuvantedandrecombinanthaseasonalinfluenzavaccinationinolderadults AT ranawakaapmperera immunogenicityofstandardhighdosemf59adjuvantedandrecombinanthaseasonalinfluenzavaccinationinolderadults AT denniskmip immunogenicityofstandardhighdosemf59adjuvantedandrecombinanthaseasonalinfluenzavaccinationinolderadults AT jsmalikpeiris immunogenicityofstandardhighdosemf59adjuvantedandrecombinanthaseasonalinfluenzavaccinationinolderadults AT markgthompson immunogenicityofstandardhighdosemf59adjuvantedandrecombinanthaseasonalinfluenzavaccinationinolderadults AT benjaminjcowling immunogenicityofstandardhighdosemf59adjuvantedandrecombinanthaseasonalinfluenzavaccinationinolderadults AT sophieavalkenburg immunogenicityofstandardhighdosemf59adjuvantedandrecombinanthaseasonalinfluenzavaccinationinolderadults
_version_	1718392060847849472

Immunogenicity of standard, high-dose, MF59-adjuvanted, and recombinant-HA seasonal influenza vaccination in older adults

Ejemplares similares